Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943987 | 0.98 | ATM (0.60) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL16389743 | 0.98 | ATM (0.60) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL15224235 | 0.98 | ATM (0.60) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL15224233 | 0.98 | ATM (0.60) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL6536816 | 0.90 | LMNA (0.54) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| Succinamide SCHEMBL28868201 | 0.89 | ATM (0.68) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL729631 | 0.88 | ATM (0.74) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL11769367 | 0.86 | ATM (0.71) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL1159899 | 0.86 | ATM (0.71) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL9939066 | 0.86 | ATM (0.71) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009019508-A1 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-02-12 | — | — | WO | claimed |
| US-4409224-A | Pyrimido[1,6-a]indole derivatives | AMERICAN HOME PRODUCTS CORP. (US) | 1983-10-11 | — | — | US | claimed |
| WO-1980000537-A1 | PYRIMIDO(1,6-A)INDOLE DERIVATIVES | AMERICAN HOME PROD (US) | 1980-04-03 | — | — | WO | claimed |
| EP-0008950-A2 | Pyrimido(1,6-a)indole derivatives and intermediates therefor, processes for their preparation, pharmaceutical compositions containing the derivatives and their use | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-03-19 | — | — | EP | claimed |
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| CN-106431790-B | A kind of emulsion phosphatide base emulsifier and preparation method thereof | 江西抚州国泰特种化工有限责任公司 | 2018-07-24 | — | — | CN | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-7625462-B2 | Agent having \"triggerable\" isocyanate bonding functionality blended with papermaking fibers prior to formation of tissue web; after web is dewatered, and during or after drying, triggerable bonding functionality is activated to strengthen resulting sheet structure | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070246180-A1 | Tissue products containing triggerable polymeric bonding agents | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-10-25 | — | — | US | disclosed |
| US-4409224-A | Pyrimido[1,6-a]indole derivatives | AMERICAN HOME PRODUCTS CORP. (US) | 1983-10-11 | — | — | US | disclosed |
| US-4307234-A | Pyrimido[1,6-a]indole derivatives | AMERICAN HOME PRODUCTS CORP. (US) | 1981-12-22 | — | — | US | disclosed |
| WO-1980000537-A1 | PYRIMIDO(1,6-A)INDOLE DERIVATIVES | AMERICAN HOME PROD (US) | 1980-04-03 | — | — | WO | disclosed |
| EP-0008950-A2 | Pyrimido(1,6-a)indole derivatives and intermediates therefor, processes for their preparation, pharmaceutical compositions containing the derivatives and their use | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TAP1, TIMCC, CD81 | ATM 4597/4885ALDH1A1 4814/4885SMN1; SMN2 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.